Разработка и регистрация лекарственных средств (Jan 2019)
RESULTS OF THE PHARMACOECONOMIC STUDY OF MEDICAL CARE FOR END-STAGE RENAL FAILURE PATIENTS IN NEED OF DIALYSIS
Abstract
Budget impact analysis and cost-utility analysis for the therapy of end-stage renal failure by methods of peritoneal dialysis and hemodialysis were performed by means of a developed analytical model of decision making. Effect of impact on the budget of extension of the peritoneal dialysis program was defined. Budget impact analysis has shown that the use of peritoneal dialysis as first-line therapy for patients with end-stage renal failure is accompanied by savings of the federal budget. It has also been found that peritoneal dialysis as compared to hemodialysis is characterized as a dominant point of view of the analysis «cost-utility», having a smaller value of the coefficient «cost-utility».